The Cigna Group (CI) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
1 Aug, 2026Executive summary
Q2 2026 revenues rose 7% year-over-year to $71.7 billion, with strong performance in both Evernorth and Cigna Healthcare segments.
Adjusted income from operations for Q2 2026 was $2.1 billion ($7.78 per share), up 6% year-over-year.
Shareholders' net income for Q2 2026 was $1.66 billion–$1.7 billion, with diluted EPS up 10% year-over-year.
Full-year 2026 adjusted EPS outlook raised to at least $30.45, reflecting confidence in ongoing execution.
Continued focus on innovation, leveraging AI and technology to enhance personalized healthcare and operational efficiency.
Financial highlights
Q2 2026 total revenues: $71.7 billion; adjusted after-tax earnings: $2.1 billion; adjusted EPS: $7.78.
Evernorth revenues grew 6% year-over-year to $61.5 billion; pre-tax adjusted earnings: $1.7 billion.
Cigna Healthcare revenues up 9%–10% year-over-year to $11.8 billion; pre-tax adjusted earnings: $1.3 billion.
Specialty and Care Services pre-tax adjusted earnings up 22% year-over-year to $1.1 billion.
After-tax special item charges of $153 million ($0.58 per share) recorded in Q2.
Outlook and guidance
Full-year 2026 adjusted EPS outlook increased to at least $30.45.
Evernorth full-year pre-tax adjusted earnings expected at least $6.9 billion; Cigna Healthcare at least $4.55 billion.
Second half adjusted EPS expected to be split evenly between Q3 and Q4.
Cigna Healthcare Medical Care Ratio (MCR) forecasted between 83.7% and 84.7% for 2026; Q3 MCR expected slightly above Q2.
Outlook includes anticipated share repurchases and 2026 dividends.
Latest events from The Cigna Group
- 2024 revenue up 27% to $247.1B; 2025 outlook strong with higher EPS and capital returns.CI
Q4 20249 Jul 2026 - Specialty drug innovation and biosimilars drive rapid growth and cost savings in healthcare.CI
Bernstein Healthcare 1:1 Forum 20249 Jul 2026 - Q3 2024 revenue up 30% to $63.7B, EPS up 11%, net income down on VillageMD loss.CI
Q3 20248 Jul 2026 - Q2 2025 revenue up 11% to $67.2B, adjusted EPS $7.20, and EPS guidance reaffirmed at $29.60+.CI
Q2 20258 Jul 2026 - Rebate-free PBM model scales by 2028; specialty and AI drive growth and efficiency.CI
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 saw higher revenues, profits, and a raised outlook, driven by strong segment results.CI
Q1 20269 May 2026 - Board and management proposals passed; shareholder written consent proposal failed.CI
AGM 202622 Apr 2026 - Board recommends approval of all annual meeting items except the written consent proposal.CI
Proxy Filing13 Mar 2026 - Strong 2025 results, portfolio focus, and leadership transition headline this year’s proxy.CI
Proxy Filing13 Mar 2026